HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ng, T Articles by Macdougall, I Search for Related Content PubMed PubMed Citation Articles by Ng, T Articles by Macdougall, I

Recombinant erythropoietin in clinical practice

¹ Phase One Clinical Trials Unit Ltd, Plymouth, UK
² Sydney Haematology Oncology Clinic, Hornsby, New South Wales, Australia
³ Department of Haematology, John Radcliff Hospital, Oxford, UK
⁴ Department of Renal Medicine, King’s College Hospital (Dulwich), London, UK

Correspondence to:
Correspondence to:
Dr Thomas Ng, Phase One Clinical Trials Unit Ltd, 119 Looseleigh Lane, Derriford, Plymouth PL6 5HH, UK;
tsfng{at}hotmail.com

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.

Keywords: recombinant erythropoietin; anaemia; clinical applications

Abbreviations: G-CSF, granulocyte colony-stimulating factor; NESP, novel erythropoiesis stimulating protein; PRCA, pure red cell aplasia; RBCs, red blood cells; RHuEPO, recombinant human erythropoietin Please note that packed cell volume is used in the text; this is equivalent to haematocrit

This article has been cited by other articles:

				K. Caiola and J. W. Cheng Use of Erythropoietin in Heart Failure Management Ann. Pharmacother., December 1, 2004; 38(12): 2145 - 2149. [Abstract] [Full Text] [PDF]

				M. A Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res, August 1, 2004; 63(2): 208 - 216. [Abstract] [Full Text] [PDF]